University Of California, San Francisco

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Lymphoma, Non-Hodgkin

Interventions: Drug: Carfilzomib
Drug: Bendamustine
Drug: Rituximab

First Posted Date: 2014-07-10

Last Posted Date: 2021-04-23

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 10

Registration Number: NCT02187133

Locations: 🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
University of California, Davis, Davis, California, United States

Connecting Resources for Urban Sexual Health

Not Applicable

Completed

Conditions: HIV
Sexually Transmitted Infections

Interventions: Other: Testing and linkage to care for Y/MSM
Behavioral: Engagement and retention for HIV-positive Y/MSM in care
Other: Engagement and retention for HIV-negative Y/MSM in sexual health services
Drug: Stribild PEP Substudy

First Posted Date: 2014-07-08

Last Posted Date: 2024-12-12

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 378

Registration Number: NCT02183909

Locations: 🇺🇸
Downtown Youth Clinic, Oakland, California, United States

DuoPACT Pilot Intervention

Not Applicable

Completed

Conditions: HIV/AIDS

Interventions: Behavioral: DuoPACT
Behavioral: Life Steps

First Posted Date: 2014-07-04

Last Posted Date: 2024-02-15

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 60

Registration Number: NCT02181881

Locations: 🇺🇸
Center for AIDS Prevention Studies, San Francisco, California, United States

Assessment of Cerebral Microvascular Circulation

Not Applicable

Withdrawn

Conditions: Cerebral Microvascular Circulation

Interventions: Procedure: Mechanical ventilation adjustment

First Posted Date: 2014-07-02

Last Posted Date: 2019-01-08

Lead Sponsor: University of California, San Francisco

Registration Number: NCT02179840

Locations: 🇺🇸
UCSF, San Francisco, California, United States

GA-68 DOTA-TOC of Somatostatin Positive Malignancies

Phase 1

Terminated

Conditions: Neuroendocrine Tumor
Carcinoid Tumors
Neuroblastoma
Paraganglioma

Interventions: Procedure: Computed Tomography (CT)
Drug: Gallium Ga 68-Edotreotide
Procedure: Magnetic Resonance Imaging (MRI)
Procedure: Positron Emission Tomography (PET)

First Posted Date: 2014-06-30

Last Posted Date: 2019-11-12

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 300

Registration Number: NCT02177773

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Sirolimus Prophylaxis for aGVHD in TME SCID

Phase 2

Withdrawn

Conditions: Stem Cell Transplant
Severe Combined Immunodeficiency
Transplacental Maternal Engraftment

Interventions: Drug: Sirolimus

First Posted Date: 2014-06-30

Last Posted Date: 2015-12-03

Lead Sponsor: University of California, San Francisco

Registration Number: NCT02177760

Locations: 🇺🇸
Benioff Children's Hospital at UCSF Medical Center, San Francisco, California, United States

Nepal Elimination of Trachoma Study

Phase 2

Withdrawn

Conditions: Trachoma

Interventions: Drug: Azithromycin

First Posted Date: 2014-06-26

Last Posted Date: 2015-05-21

Lead Sponsor: University of California, San Francisco

Registration Number: NCT02176057

Locations: 🇳🇵
Geta Eye Hospital, Geta, Kailali, Nepal

Reducing Distress And Improving Glycemic Control In Adults With Type 1 Diabetes

Not Applicable

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Behavioral: 'KnowIt'
Behavioral: 'OnTrack'

First Posted Date: 2014-06-26

Last Posted Date: 2019-03-25

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 301

Registration Number: NCT02175732

Locations: 🇺🇸
UC San Francisco, Family and Community Medicine Dept., San Francisco, California, United States

Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Adenocarcinoma

Interventions: Drug: Goserelin Acetate
Behavioral: Behavioral Dietary Intervention
Other: Laboratory Biomarker Analysis
Other: Counseling
Other: Educational Intervention
Drug: Leuprolide Acetate
Other: Quality-of-Life Assessment
Behavioral: Exercise Intervention
Drug: Triptorelin Pamoate

First Posted Date: 2014-06-20

Last Posted Date: 2020-07-23

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 57

Registration Number: NCT02168062

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve

Not Applicable

Terminated

Conditions: Hepatocellular Carcinoma
Chemoembolization

Interventions: Device: LC Bead

First Posted Date: 2014-05-26

Last Posted Date: 2019-09-10

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 17

Registration Number: NCT02147301

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy